PE82799A1 - Compuestos de urea n-sustituida inhibidores de farnesilo transferasa - Google Patents

Compuestos de urea n-sustituida inhibidores de farnesilo transferasa

Info

Publication number
PE82799A1
PE82799A1 PE1998000506A PE00050698A PE82799A1 PE 82799 A1 PE82799 A1 PE 82799A1 PE 1998000506 A PE1998000506 A PE 1998000506A PE 00050698 A PE00050698 A PE 00050698A PE 82799 A1 PE82799 A1 PE 82799A1
Authority
PE
Peru
Prior art keywords
farnesilo
transferasa
inhibitors
substituted
urea compounds
Prior art date
Application number
PE1998000506A
Other languages
English (en)
Inventor
Alan K Mallams
Stacy W Remiszewski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE82799A1 publication Critical patent/PE82799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) O SU SAL, DONDE A ES N o N-OXIDO; CUANDO X ES N o CH SE UNE CON UN ENLACE SIMPLE AL C11 o CUANDO X ES C SE UNE CON UN ENLACE DOBLE AL C11; X1 Y X2 SON BROMO O CLORO; UNO DE X3 Y X4 ES H Y EL OTRO ES BROMO, CLORO; Y1 E Y2 SON H O ALQUILO; Z ES =O o =S; R5, R6, R7 Y R8 SON H, CF3, -COR10, ALQUILO O ARILO; O R5 Y R6 O R7 Y R8 SON =O o =S; R10, R19 Y R20 SON H, ALQUILO, ALCOXI, ENTRE OTROS; CUANDO R19 ES H, R20 NO ES H; v ES 0-3; w ES 0-1. EL COMPUESTO I INHIBE A LA ENZIMA FARNESILO RAS TRANSFERASA, INHIBIENDO EL CRECIMIENTO ANORMAL DE CELULAS TUMORALES QUE EXPRESAN UN ONCOGEN RAS ACTIVADO COMO LAS CELULAS TUMORALES PANCREATICAS, CELULAS DE CANCER DE PULMON, CELULAS TUMORALES DE LEUCEMIA MIELOIDE, CELULAS TUMORALES DEL FOLICULO DE TIROIDES
PE1998000506A 1997-06-17 1998-06-15 Compuestos de urea n-sustituida inhibidores de farnesilo transferasa PE82799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
PE82799A1 true PE82799A1 (es) 1999-08-26

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000506A PE82799A1 (es) 1997-06-17 1998-06-15 Compuestos de urea n-sustituida inhibidores de farnesilo transferasa

Country Status (14)

Country Link
EP (1) EP0989979A1 (es)
JP (1) JP2002506444A (es)
KR (1) KR20010013881A (es)
CN (1) CN1267291A (es)
AR (1) AR013094A1 (es)
AU (1) AU8253598A (es)
CA (1) CA2293706C (es)
CO (1) CO4940458A1 (es)
HU (1) HUP0002954A3 (es)
IL (1) IL133389A0 (es)
NZ (1) NZ501571A (es)
PE (1) PE82799A1 (es)
WO (1) WO1998057948A1 (es)
ZA (1) ZA985205B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU2002211862B2 (en) * 2000-10-05 2007-03-15 George Q. Daley Methods of inducing cancer cell death and tumor regression
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
JP4769082B2 (ja) * 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
EP3401314B1 (en) * 2013-03-15 2023-11-08 Araxes Pharma LLC Covalent inhibitors of kras g12c
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2016164675A1 (en) 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
JP7015059B2 (ja) 2015-11-16 2022-02-15 アラクセス ファーマ エルエルシー 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
JP2020521742A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Ｋｒａｓの共有結合性阻害剤
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
EP1019392B1 (en) * 1995-12-22 2005-11-09 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
TR199901275T2 (xx) * 1996-09-13 1999-09-21 Schering Corporation Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
KR20000036103A (ko) * 1996-09-13 2000-06-26 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제의 억제에 유용한 치환된벤조사이클로헵타피리딘 유도체

Also Published As

Publication number Publication date
ZA985205B (en) 1998-12-15
KR20010013881A (ko) 2001-02-26
IL133389A0 (en) 2001-04-30
CN1267291A (zh) 2000-09-20
WO1998057948A1 (en) 1998-12-23
NZ501571A (en) 2002-02-01
EP0989979A1 (en) 2000-04-05
CA2293706A1 (en) 1998-12-23
CO4940458A1 (es) 2000-07-24
AU8253598A (en) 1999-01-04
AR013094A1 (es) 2000-12-13
HUP0002954A2 (hu) 2001-06-28
JP2002506444A (ja) 2002-02-26
HUP0002954A3 (en) 2002-11-28
CA2293706C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
PE82799A1 (es) Compuestos de urea n-sustituida inhibidores de farnesilo transferasa
PE20091343A1 (es) Compuestos derivados de heterociclo biciclicos como moduladores de gpr119
AR056692A1 (es) Blanqueo de substratos
CO5540346A2 (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo [2,3-d] pirimidina
MX9305812A (es) 3-(2-aciloxietoxifenil)benzofuran-2-onas para utilizarse como estabilizantes.
ECSP099638A (es) Nuevo compuesto de adenina
DE60008574D1 (de) Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
ES2182829T3 (es) Hidroxifenil-s-triacinas.
IT1264451B1 (it) 3-(carbossimetossifenil)-benzofuran-2-oni come agenti stabilizzanti
PE20071033A1 (es) Compuestos heterociclicos como inhibidores de la interaccion de proteinas bcl
PE20001516A1 (es) Compuestos triciclicos como inhibidores de la farnesil transferasa
BR9713160A (pt) Composição utilizável em alvejamento
MX9405324A (es) Aductos de epoxidos de amina impedida como estabilizantes.
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
DE50005444D1 (de) Selektive inhibitoren des urokinase-plasminogen aktivators
ES2177816T3 (es) Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas.
TR200201783T2 (tr) 5-Siyanofatalid hazırlamak için yöntem
BR0115996A (pt) Sulfamidotienopirimidinas
ECSP045200A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
PE86199A1 (es) Sulfonamida inhibidor de la enzima farnesilo transferasa
ATE214403T1 (de) Verwendung von reaktiven, präpolymeren organischen verbindungen
AR027022A1 (es) Un sistema catalizador de blanqueo, una composicion blanqueadora, y un proceso de limpieza.
MXPA94005411A (es) Compuestos novedosos de piperidina para utilizarsecomo estabilizantes para materiales organicos.
ES2066187T3 (es) Compuestos de fosforo.
DE50003001D1 (de) Verwendung von porphyrinderivaten in aquarien

Legal Events

Date Code Title Description
FC Refusal